The company is engaged in translational research and analysis of tumor diseases using genomic and proteomic analyses as well as patient-specific cell culture models.
Products, services, technology
We have developed a diagnostic method that allows prediction of cancer drug’s effectiveness on each patient’s tumor model. This highly-personalized diagnostic method is a valuable tool in modern precision oncology. Results are made available within short notice - approx. 30 days.
Our goal in a first step is to conduct clinical testing together with a strong partner in Switzerland. In due time we like to make our diagnostic method available to the general public. Together with a strong partner we are planning to build-up a local infrastructure / laboratories.